CFDs are complex instruments. You can lose your money rapidly due to leverage. Please ensure you understand how this product works and whether you can afford to take the high risk of losing money. CFDs are complex instruments. You can lose your money rapidly due to leverage. Please ensure you understand how this product works and whether you can afford to take the high risk of losing money.

Fever-Tree share price: what’s the latest ahead of its January trading update?

The premium producer of carbonated mixers will release a trading update next week, with analysts from HSBC and Liberum Capital reiterating their ‘buy’ ratings in January.

Fever-Tree is up more than 10% this week ahead of its trading update on January 21 (Tuesday), with the company reporting impressive sales growth over the last four years - a trend the drinks maker hopes to continue in its results next week.

In its last trading update in November, the drinks maker reported sales growth across all four operating regions and expects to record double-digit revenue growth in 2019.

‘We continue to see growth across all four regions,’ Fever-Tree CEO Tim Warrillow said. ‘Indeed, sales accelerated in our key growth markets of the US and Europe.’

‘Fever-Tree's progress in the US is particularly encouraging and the signing of a US bottling partner is a further step in building our operations in this exciting market,’ he added.

Fever-Tree is trading at £20.97 a share as of 15:50 GMT on Wednesday.

Looking to trade Fever-Tree? Open a live or demo account with IG.

Will Fever-Tree hit revenue targets?

Following a strong performance across all four regions, the company now expects to generate total revenue of between £266 million to £268 million, representing 12% - 13% growth, with margin forecasts unchanged.

Analysts had been forecasting sales of between £272 million to £275 million in 2019.

Investors will be eager to see if the company can meet expectations next week, with a strong set of results capable of sending its share price higher.

HSBC and Liberum Capital reiterate ‘buy’ rating

Analysts from HSBC and Liberum Capital reiterated their ‘buy’ rating for the stock in January ahead of the company’s latest trading update.

Both left their previous price targets for the stock unchanged, with HSBC and Liberum Capital issuing targets of £33 and £28.25 respectively.

Based on the stock trading at £20.97 the pair believe it has a potential upside of 34.7% and 57.4%.

You can go long or short Fever-Tree with IG using derivatives like CFDs and spread bets.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.